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 Ritonavir and cobicistat, used as pharmacokinetic enhancers in 
combination with some antiretrovirals (ARVs) for the treatment 
of HIV, are potent inhibitors of the CYP3A4 isoenzyme. Most 
glucocorticoids are metabolised via the CYP3A4 pathway and 
iatrogenic Cushing’s syndrome (ICS), with possible secondary 
adrenal insufficiency (SAI), is a recognised complication 
following co-administration with ritonavir or cobicistat. A 
structured approach for identifying and managing potentially 
affected individuals has not been established. 
 We systematically identified patients with ICS/SAI and found 
substantial heterogeneity in clinical practice across three large 
London HIV centres. While this significant drug interaction and 
its complications are now well-recognised, it is apparent that 
there is no standardised approach to management or guidance 
for the general physician. Here we describe the management of 
ICS/SAI in our current practice, review the available evidence 
and suggest practice recommendations. 
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 Introduction 
 Ritonavir and cobicistat are pharmacokinetic enhancers 
used in the treatment of HIV infection. They are extremely 
potent inhibitors of cytochrome P450 3A4 (CYP3A4) activity. 








 Iatrogenic Cushing’s syndrome due to drug interaction 
between glucocorticoids and the ritonavir or cobicistat 
containing HIV therapies 
at sub-therapeutic doses, in combination with HIV protease 
inhibitors (PIs), to significantly increase their concentrations 
and allow less frequent and lower dosing. 1 Cobicistat was 
developed more recently and is similar in structure. It is used in 
combination with PIs or elvitegravir (an integrase inhibitor) 2 
but has no antiretroviral activity itself. 3 
 The downside of this pharmacokinetic manipulation is the 
significant potential for interactions with CYP3A4 substrates, 
leading to side effects. CYP3A4 is the dominant isoenzyme of the 
hepatic cytochrome P450 system and is the primary metabolic 
step for the degradation of endogenous and most prescribed 
corticosteroids. The metabolism of these can therefore be 
decreased by inhibitors such as ritonavir/cobicistat. 4 Subsequent 
increases in exogenous corticosteroid plasma concentrations and 
half-life can lead to iatrogenic Cushing’s syndrome (ICS) 5 and, at 
supraphysiological levels, to suppression of adrenocorticotropic 
hormone (ACTH) and endogenous corticosteroid secretion, 
potentially resulting in secondary adrenal insufficiency (SAI). 
There is abundant evidence highlighting this issue. 1,6–11 
However, a structured approach to identify and manage 
potentially affected individuals has not been established. We aim 
to summarise the current management of ICS/SAI in three large 
HIV patient cohorts, review the available literature and develop 
practice recommendations. Of note, cobicistat became available 
after the evaluation period covered; however, all advice for 
ritonavir is applicable to it. 12 
 Methods 
 Service evaluation 
 This evaluation was carried out at three centres: Royal Free 
Hospital, London (A), Mortimer Market Centre, University 
College Hospital, London (B) and Chelsea and Westminster 
Hospital, London (C). Patients with ICS/SAI were systematically 
identified through a search of clinic letter databases (centres A 
and B), pathology results (centres B and C ) and/or radiology 
interventions (centre A) at these three London HIV tertiary 
centres over a 9-month period. For the letter database search, 
search terms cortisol, budesonide, triamcinolone and fluticasone 
were used. For the pathology search, all cortisol and short 
synacthen test (SST) results for patients with HIV in the 
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evaluation period were reviewed. Centre A also evaluated all 
radiological interventions in HIV patients during the study 
period. Not all search modes were available in all three centres. 
For instance, some software used does not permit mass scanning 
of individual clinic letter content and not all pathology/
radiology departments had the resources to release data. 
 Case notes were then reviewed retrospectively for all identified 
cases. Presenting features, steroid indication, formulation, doses 
and route, concurrent antiretrovirals (ARVs), investigations 
and management were recorded. 
 As a service evaluation, ethical approval was not required in 
accordance with NHS Health Resource Authority guidance. 
 Literature review 
 The available literature was reviewed using the bibliographic 
database PubMed and the following search terms: iatrogenic 
Cushing’s/Cushing syndrome, secondary adrenal insufficiency, 
ritonavir, corticosteroids, glucocorticoids, fluticasone, 
budesonide, mometasone, triamcinolone, methylprednisolone, 
prednisolone, CYP3A4 inhibitors and HIV. 
 Results 
 Service evaluation 
 The service evaluation ran from 31 January 2012 to 1 October 
2012. From a combined cohort of approximately 15,000 patients , 
19 cases of confirmed ARV-steroid interactions leading to ICS/
SAI were identified over 9 months (three in centre A, seven in 
centre B and nine in centre C). Cases are described in detail 
in Table S1; 13 out 19 cases were male and ages ranged from 
36 to 64 years . Overall, the main indications for steroid use 
were asthma/chronic obstructive pulmonary disease (COPD) 
(n=8) and musculoskeletal (n=6). Twelve patients presented 
with typical features of Cushing’s syndrome and seven with 
symptoms consistent with adrenal insufficiency. Fluticasone 
(inhaled or nasal) was the culprit steroid in over a half of cases 
(n=10). There was one case of topical steroid use. 
 Large intercentre differences in investigations and 
management were seen: 14 out of 19 patients had a 9 am 
cortisol measured in their HIV clinic, with evidence of 
adrenal suppression seen in most (n=12). Meanwhile, only 
10 patients had a documented SST, all with confirmed SAI. 
Two patients had investigations carried out by their GPs, but 
seven did not have an SST (mainly in centre C, n=5). For these 
patients, clinical findings and/or the 9 am cortisol (range: 
11–301 nmol/L) were cited as diagnostic. 
 With regards to pharmacological management, 58% (n=11) 
switched or stopped the steroids alone, 21% (n=4) switched 
ARV alone and 21% (n=4) did both. Centre B ceased use of the 
steroid in all of its patients, unlike A and C. Centre A switched 
ARVs in all of its patients (while continuing steroids in two of 
the three patients), whereas centre B switched ARVs in two of 
nine patients and C in three of seven, seemingly unrelated to 
whether the steroid had been injected. 
 Over half of patients (n=11) received hydrocortisone (HC) 
replacement, the majority of which were in centres A (3/3) and 
B (6/9), while centre C prescribed HC in only two patients, 
even when background steroids had been stopped. Initial HC 
replacement dose varied from a total daily dose of 20 mg in 
three divided doses (10/5/5 mg) to just 10 mg once daily. The 
duration of treatment ranged from 2 to 72 weeks. 
 Overall, ten patients were co-managed with the endocrinology 
team. Centre A co-managed all of its cases, while centre B co-
managed five patients and centre C two. Advice on emergency 
steroid cover was documented in only eight cases (38%) and 
only one case was reported as a serious untoward incident. 
 Nine patients (48%) had documented monitoring for 
hypothalamic-pituitary-adrenal (HPA) axis recovery (mainly 
centres A and B). Documented recovery time ranged from 
12 weeks to not recovered at 3.5 years. Correspondence to primary 
care physicians (GPs) was sent for all except three patients; these 
three patients did not wish to disclose their HIV status. 
 Literature review 
 The literature was reviewed up to January 2016 and referenced 
search results range from 1994 to 2015. 
 Features and timing of ICS and SAI 
 The manifestations of ICS and adrenal insufficiency are 
summarised in Table  1 . Some manifestations of glucocorticoid 
excess occur quickly (hours/days), for example psychiatric 
effects and increased appetite, whereas a cushingoid 
appearance, glucose intolerance or osteoporosis may take 
longer to develop (weeks/months). 13 In our cohort, changes 
in appearance (weight gain, striae, proximal myopathy) and 
fatigue were the commonest presenting features; however, 
presentations can vary significantly. 6–11 
 Although glucocorticoid treatment courses of less than 
3 weeks duration often will not lead to HPA axis suppression, at 
relatively high doses, significant HPA suppression can occur in 
as little as 5 days. 13,14 Longer-acting glucocorticoid formulations 
are associated with a higher risk of SAI. 15,16 
 Table 1.  Signs and symptoms of iatrogenic 
Cushing’s syndrome and secondary adrenal 
insufficiency 
Features of iatrogenic 
Cushing's syndrome
Features of secondary 
adrenal insufficiency
 >  Weight gain – central 
obesity with redistribution 
of body fat to truncal 
areas, dorsocervical and 
supraclavicular fat pads 
 >  Moon face 
 >  Plethora 
 >  Easy bruising 
 >  Thin skin 
 >  Dark abdominal striae 
 >  Proximal myopathy 
 >  Susceptibility to infections 
 >  Depression and psychosis 
 >  Avascular necrosis 
 >  Osteoporosis – trabecular 
rather than cortical bone loss 
(vertebrae and ribs) 
 >  Weakness/fatigue 
 >  Malaise 
 >  Nausea 
 >  Vomiting 
 >  Abdominal pain 
 >  Anorexia/weight loss 
 >  Myalgia 
 >  Arthralgia 
 >  Hypotension 
 >  Decreased consciousness 
 >  Lethargy 
 >  Unexplained hypogly-
caemia 
 >  Hyponatremia 
 >  Seizure 
 >  Coma 
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 Current evidence on individual glucocorticoids by route 
 Inhaled 
 Fluticasone causes more cortisol suppression than other inhaled 
steroids (including beclomethasone, budesonide, triamcinolone 
and flunisolide) because of its longer half-life and its higher 
binding affinity for the glucocorticoid receptor. 17 Manufacturers 
of fluticasone specifically warn of co-administration with 
ritonavir. 18 Drug interactions are also well described between 
budenoside and ritonavir. 6,7,19 Conversely, there are no reported 
cases with beclomethasone interaction as it is predominantly 
metabolised by esterase hydrolysis; 20 CYP3A4 is minimally 
involved. In a randomised healthy volunteer study, the addition 
of ritonavir to inhaled beclomethasone doubled the area under 
the curve (AUC) for the serum concentration of the active 
metabolite of beclomethasone, but with no significant reduction 
in basal or stimulated serum cortisol levels. 20 
 Nasal 
 SAI secondary to nasal fluticasone is well documented, whereas 
beclomethasone is not predicted to cause cortisol suppression. 12,18 
A few cases on mometasone have been published but with 
unclear contributory effect on symptoms. 21,22 Therefore, 
while not thought to cause more cortisol suppression than 
beclomethasone, 23 mometasone is metabolised via CYP3A4 and 
caution is advised. 
 Intra-articular or epidural 
 ICS/SAI have been observed with intra-articular triamcinolone 
and methylprednisolone administered without pharmacological 
boosting. 24,25 In HIV, there are at least 30 published cases of 
ICS/SAI following intra-articular/epidural steroid in patients 
on antiretrovirals; 8–11,26 26 were on ritonavir and 4 on other 
ARVs. All of these patients were injected with triamcinolone, 
except one who was injected with methylprednisolone. 8–11,26–30 A 
retrospective review reported an 11% event frequency, with the 
biggest risk factor being two or more injections within 6 months. 26 
 Interestingly, a recent randomised controlled trial 
demonstrated no efficacy advantage of triamcinolone over 
methylprednisolone for knee osteoarthritis (in a non-HIV 
population). 31 Methylprednisolone is metabolised by the 
CYP3A4 enzyme and ICS/SAI following co-administration 
with a pharmacological CYP3A4 inhibitor is theoretically 
possible. 32 However, in view of strong evidence of ICS/SAI with 
triamcinolone, no efficacy benefit and only one case reported 
with methylprednisolone, the latter may be preferable in 
patients on ritonavir/cobicistat. 
 Topical and ocular 
 ICS/SAI are widely reported with the use of potent topical 
steroids over a wide skin surface area in patients without 
HIV. 33 As such, the risk of systemic absorption and 
pharmacological boosting of topical steroids in the context of 
ritonavir or cobicistat is real and warrants close monitoring. 
Two cases of low morning cortisol/ACTH following 
concomitant use of ritonavir and topical triamcinolone have 
been reported at a conference, but none in the published 
literature. 21 Outside the use of CYP3A4 inhibitors, ICS has only 
been reported on a few occasions with ocular steroid drops 34 
and in two cases in the context of ritonavir. 35,36 
 Oral 
 A 30–40% increase in AUC has been reported in healthy 
volunteers taking prednisolone with ritonavir, 37 and there is 
one case of ICS with the use of oral budesonide and ritonavir. 19 
 Discussion 
 Using a systematic approach, our review identified 19 cases of 
significant drug-drug interactions between ARVs and steroids 
over 9 months across three large HIV centres. There were 
substantial inter-centre discrepancies in investigations and 
management. 
 Not all patients with clinical signs had a 9 am cortisol carried 
out and just over half underwent dynamic testing (depending 
on the centre). For those who did not have an SST, clinical 
findings and the 9 am cortisol were used. Interestingly, three 
patients did not even meet the cortisol cut offs recently 
suggested by Tomlinson  et al as sufficient to justify avoiding 
an SST (<35 and >348 nmol/L in patients taking inhaled 
glucocorticoids). 14 
 Just over half of patients were co-managed with the endocrine 
team; this was unevenly distributed across the centres 
and may reflect the availability of local referral pathways. 
Pharmacological management was also very varied, with 
some clinicians stopping/switching the steroid alone, others 
switching the ARVs and stopping the steroid and some opting 
to switch ARVs only. There was no clear relationship with the 
steroid method of administration (eg injected). While this will 
be influenced in parts by the patient’s clinical situation and 
viral resistance profile, it may also reflect a lack of consensus 
in clinical priority among practitioners (ARVs versus steroid). 
Communication with GPs was high across all centres. 
 These findings highlight a lack of a standardised approach 
to practice, possibly reflecting the lack of published guidance 
available. Here, we suggest practice recommendations for 
the prevention, investigation and management of drug 
interactions between steroids and pharmacologically enhanced 
antiretrovirals, with the aim of providing guidance and 
reducing heterogeneity in practice. 
 Prevention of pharmacological interaction via safe 
prescribing in patients treated with CYP3A4 inhibitors 
 Routine use of potent steroids metabolised via CYP3A4, 
including fluticasone, budesonide and triamcinolone in 
patients treated with CYP3A4 inhibitors is not recommended 
via any route. If unavoidable, the HIV team should review the 
possibility of a switch to a non-ritonavir/cobicistat containing 
regimen, carefully considering known or likely resistance to 
HIV drugs. This should ideally precede the introduction of the 
steroid. If co-administration of ritonavir/cobicistat with a high-
risk steroid absolutely cannot be prevented, clear interspecialty 
(including GP) communication and close monitoring are 
critical. A risk-benefit discussion with the patient is important. 
 Recommendations for inhaled/intranasal steroids 
 The preferred alternative to fluticasone and budesonide, via 
inhaled or nasal route, is beclomethasone. The use of steroid 
sparing interventions should be considered in conjunction with 
the appropriate specialty team. 
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 Recommendations for injectable steroids 
 Triamcinolone is not recommended in patients on ritonavir/
cobicistat. Intra-articular methylprednisolone may be used 
as an alternative, although the potential for ICS and SAI 
still exists. Some centres advise a dose reduction of 30% for 
methylprednisolone; however, this is guided by expert opinion 
only. Non-steroid options in this setting are preferable. 
 Recommendations for oral steroids 
 Duration of use of oral steroids should be kept to a minimum, 
depending on the initial indication, with a switch to a steroid-
sparing regimen as soon as possible. Consideration should 
be given to dose modification and potential for steroid taper, 
although there is little evidence to guide this. 
 Recommendations for topical steroids 
 The prolonged use of topical corticosteroids (depending on 
the steroid potency, skin condition, surface body area and 
involvement of face, groin, and/or axillary regions) with 
CYP3A4 inhibitors poses a risk of CSI/SAI. 22,33 Steroid sparing 
alternatives should be sought with dermatology input. 
 Prevention of pharmacological interaction via 
integration and patient empowerment 
 In the UK, ARVs are prescribed by HIV clinicians and 
dispensed via hospital pharmacies or home delivery. Non-
HIV medications, such as steroids, are usually prescribed by 
non-HIV clinicians and dispensed locally or bought over the 
counter. Consequently, potential interactions that would be 
detected if drugs were prescribed or dispensed at the same 
site may go unnoticed. Although there have been national 
efforts to communicate HIV drug interaction information 
to GPs, treatment decisions (eg triamcinolone injections) 
may occur in other clinical settings and interactions may be 
missed. Additionally, patients with HIV may not disclose their 
status to other treating physicians. In light of this, two centres 
have produced a patient information leaflet about potential 
interactions with antiretroviral boosters (Fig  1 ) . 
 Recommendations 
 >  All clinicians should assess the potential for drug-drug in-
teractions with prescribed medicines, including steroids, and 
seek advice from the HIV specialist team where identifi ed. 
Multiple sources are available, eg Liverpool HIV drug interac-
tions website ( www.hiv-druginteractions.org ), prescribing 
interaction checkers or the British National Formulary. Advice 
may vary between sources. 38 
 >  A general warning for potential drug interactions with all 
medicines and resources should be included in all clinic letters. 
 >  Appropriate incident reporting, feedback and education will 
contribute to incident prevention. 
 >  Patients should be advised to check for drug interactions with 
all new medicines. Patient information and education may 
help prevent harmful interactions. 
 Investigation of ICS/SAI and management of high-
risk co-prescription 
 Once a potential drug interaction has been identified, the 
excessive exogenous steroid needs to be discontinued and the 
 Fig 1.  Patient information leafl et on potential drug interactions between glucocorticoids and antiretroviral boosters. 
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patient investigated for ICS/SAI (Fig 2), where the most striking 
biochemical finding is a suppressed endogenous serum cortisol. 
While ICS is a clinical diagnosis, a 9 am cortisol is useful as 
a screening test for consequent SAI. 14 A 9 am cortisol of less 
than 100 nmol/L usually indicates deficient basal secretion 
or the presence of a potent exogenous steroid. A cortisol of 
greater than 550 nmol/L shows an intact HPA axis. 13 Of note, 
many use a lower threshold of greater than 450 nmol/L and 
greater than 348 nmol/L has been suggested in those on current 
inhaled glucocorticoids. 14,39 Nevertheless, patients who have 
9 am cortisol levels of less than 450 nmol/L should be further 
investigated. The standard SST is the most frequently used test 
in this context 40 where 0 minute, 30 minute and 60 minute 
cortisol levels are measured after a 250 µg tetracosactide 
injection. Cortisol thresholds and assays may vary and should 
be checked with the local laboratory. Plasma ACTH is also low 
but this test is not routinely used. 39 
 Concomitant synthetic steroid use can interfere with cortisol 
measurements. Screening should therefore be timed, if possible, 
at least 1 week after the exogenous glucocorticoid has been 
tapered to a physiological dose or removed. 13 Prolonged 
released formulations (intra-articular and epidural, especially 
triamcinolone), cause low level cortisol and a blunted response 
to ACTH stimulation for 4–6 weeks, outside of CYP3A4 
inhibition 41,42 and likely for longer with it. Test results need to 
be interpreted with caution and with endocrinology input. In 
asymptomatic patients, it may be prudent to delay testing for 
4–6 weeks post steroid injection. 
 Recommendations 
>  A 9 am cortisol level is helpful to rule out SAI (>450 nmol/L, 
bearing in mind local variation). 
 >  For 9 am cortisol <450 nmol/L, an SST will distinguish 
patients with intact HPA axis from those with SAI. This test 
is not suitable for patients on current supraphysiological 
exogenous steroids and should be organised and interpreted 
with the endocrine team. 
Is the paent receiving CYP3A4 and concomitant steroid via any route?
Unlikely Careful ongoing 
clinical 
monitoring
Is there potenal for drug-drug interacon with steroid?  
(discuss with pharmacist/specialist)
Inhaled/nasal/oral/topical steroids Injectable steroidsYes
Conduct joint review of the steroid first with specialist/endocrine/HIV teams:
• inhaled steroids – switch to beclomethasone or a steroid-sparing agent
• oral steroids – minimise dose and duraon, consider switch to steroid sparing agents
• topical steroids – limit exposure, consider switch to steroid sparing agents.
If steroid with high interacon risk is unavoidable, discuss with HIV team to remove
CYP3A4 inhibitor where possible. 
IM/IA/epidural:
• This cannot be removed so discuss with HIV 
   to switch CYP3A4 inhibitor.
• If not possible, monitor closely.
• Avoid further injecons – consider DMARDs
   in future.
If paent acutely unwell, 
hypotensive ± hyponatraemic:
measure serum corsol, commence
steroid replacement and discuss with
endocrine team Arrange for 9 am corsol
If 9 am corsol ≥450 nmol/L*, monitor clinically
No need for further tesng unless very high index
of suspicion of SAI
If ongoing exposure to CYP3A4 inhibitor and steroid,
return to top of chart and follow
Other steps:
• paents with SAI – provide informaon leaflet with
 steroid sickness rules and advise to aend A&E if 
 they become unwell
• complete incident form and inform paent's GP 
 and other relevant specialists.
If 9 am corsol <450 nmol/L*, arrange for SST
If SST normal (peak
corsol >550 nmol/L*),
no need for further
tesng. Monitor
closely
If abnormal SST (peak corsol <550 nmol/L*),
start steroid replacement in paents with
symptoms of adrenal insufficiency 
In asymptomac paents, discuss with local
endocrine team
Repeat the morning corsol and/or the
SST every 8 weeks in order to assess for
recovery of the HPA axis
Stop any steroid replacement once 9 am
corsol ≥450 nmol/L* or post SST corsol
>550 nmol/L
If ongoing exposure to
CYP3A4 inhibitor and
steroid, return to top
of chart and follow
 Fig 2.  Investigation and management pathway for patients with potential or suspected glucocorticoid-CYP3A4 inhibitor interaction (expert opinion). 
*Depending on local assay. A&E = accident and emergency department; DMARD = disease-modifying antirheumatic drugs; HPA = hypothalamic-pituitary-
adrenal; IA = intra-articular; IM = intra-muscular; SAI = secondary adrenal insuffi  ciency; SST = short synacthen test . 
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>  Exogenous steroid cessation is dependent on the route of 
administration:
 •  inhaled/intranasal – switch to beclomethasone or steroid-
sparing agent 
 •  oral – ensure only physiological (replacement) dose is 
administered 
•  topical – discuss with dermatology for steroid sparing agents 
•  injected – stop further administrations, consider disease-
modifying agents. 
 In asymptomatic patients, it is recommended to stop/switch 
the potent steroid prior to investigations. The patient should 
be warned of potential symptoms of adrenal insufficiency 
and advised to seek urgent medical attention for steroids 
and investigation if these develop. An information leaflet 
can be provided. Some specialists opt to prescribe empirical 
hydrocortisone cover prior to investigations. Local endocrinology 
team input is recommended. If steroid cessation is clinically 
impossible, discuss with the HIV team to consider switching 
ARVs. Do not cease steroids and ritonavir/cobicistat at the same 
time, without steroid replacement cover or evidence of an intact 
HPA axis. 
 In  symptomatic patients with suspected SAI, start hydrocortisone 
20 mg/day in 2–3 divided doses before planning investigations. If 
the patient is acutely unwell, hypotensive and/or hyponatraemic, 
measure serum cortisol, commence stress dose steroid 
replacement therapy and discuss with the endocrine team. 
 On the day of cortisol/SST testing, hydrocortisone is withheld 
until the test has ended, as is the previous evening’s dose. 
 In patients with confirmed SAI, repeat 9 am cortisol/SST at 
regular intervals (for example every 8 weeks) to identify and 
document HPA axis recovery. 
 Treatment of patients with symptomatic SAI 
 Symptomatic patients with SAI should be treated with daily 
replacement glucocorticoids doses plus ‘stress doses’ during 
physiological stress (illness, injury or surgery). 13,16 Physiological 
glucocorticoid doses are equivalent to prednisolone 
5.0–7.5 mg/day, or hydrocortisone 20 mg/day (in 2–3 doses). 
Because of the short half-life of hydrocortisone, there may be 
more opportunity for the HPA axis to recover compared with 
longer acting steroids. 13 Stress dose steroids usually involve 
doubling the oral glucocorticoid dose, or the use of parenteral 
steroids in patients unable to have oral steroids. 16 An individual 
with biochemical evidence of SAI in the absence of symptoms 
is also at risk of adrenal crisis during physiological stress and 
should receive ‘stress doses’, with or without daily physiological 
glucocorticoids. There is no evidence that treating asymptomatic 
patients with SAI delays the recovery of the HPA axis. 
 Recommendations 
 >  Treat all symptomatic patients with SAI with oral 
replacement glucocorticoids doses, such as hydrocortisone 
20 mg/day in 2–3 divided doses, typically 10 mg on waking, 
5 mg at 12:00 and 5 mg at 16:00, or prednisolone 
5.0–7.5 mg/day in a single morning dose. 
>  Provide all patients with SAI with written advice including 
stress doses of steroids (eg  www.addisons.org.uk/publications ). 
 >  Manage care jointly with the HIV and endocrine teams. 
 Limitations 
 The methods adopted in this service evaluation only identified 
symptomatic and diagnosed patients and is likely to have 
underestimated the actual incidence of ICS/SAI. Data from 
patients’ records did not allow accurate assessment of the 
duration of steroid therapy and we were not able to analyse 
data from patients who were investigated by their GP. 
 Conclusion 
 Using a systematic approach, we identified patients with ICS 
and SAI following co-prescription of ARVs and steroids and 
found significant variability in clinical practice across three 
large London centres. The key to prevention is prospective 
identification and avoidance of the harmful drug interaction 
through communication and increased awareness among 
clinicians and patients with HIV. We have produced a relevant 
patient information leaflet and clear joint recommendations in 
order to manage these patients safely. 
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